Sex steroid hormones have been shown to affect adrenocortical function and trophism, yet little is known about androgen action in human adrenocortical gland. In this study we examined the effects of androgens on transforming growth factor-␤1 (TGF␤1) production by the human adrenocortical cell line, NCI-H295, which we recently demonstrated to express androgen receptor and whose growth is significantly reduced by dihydrotestosterone (DHT) treatment.
increase in TGF␤1 messenger ribonucleic acid expression and in biologically active TGF␤1 protein levels in the conditioned media of NCI-H295 cells, demonstrating that androgen can induce TGF␤1 expression and production. TGF␤1 (10
Ϫ6 mol/L) was capable of significantly reducing cell proliferation (P Ͻ 0.05) after 24 h of treatment, as assessed by measuring [ 3 H]thymidine incorporation in NCI-H295 cells. The addition of TGF␤1-neutralizing antibody to cell cultures treated with different DHT concentrations (10 Ϫ9 and 10
Ϫ10
mol/L) blocked the inhibitory effect of TGF␤1 on adrenocortical cell proliferation. These findings suggest that TGF␤1 exerts an inhibitory action on adrenocortical cell proliferation. Therefore, it might be reasonable to suppose that DHT could also influence human adrenocortical cell growth by involving TGF␤1. T RANSFORMING growth factor-␤ (TGF␤) family includes five homodimeric peptide growth factors (1, 2) that play an important role in modulating growth, development, and differentiation. TGF␤ has been shown to regulate mesodermal cell differentiation and potently inhibit the proliferation of various neoplastic epithelial cells types, including those of hormone-regulated tissues such as mammary gland and prostate (3, 4) . In particular, several studies have indicated that TGF␤1 is an important negative regulator of human fetal adrenal development (5) , with marked effects on steroid-producing cell function. On the other hand, it has been suggested that members of the steroid hormone superfamily and related compounds can regulate in vitro the production of distinct TGF␤ subtypes in several tissues (bone, breast, prostate, and skin) (6) .
We previously demonstrated that the androgen receptor (AR) is expressed in human adrenal cortex and the cancer cell line, NCI-H295, and that dihydrotestosterone (DHT) significantly reduces human adrenocortical cell growth in vitro (7) . The mechanism by which DHT exerts this inhibitory action on the adrenal cortex is still unknown. Recently, we have shown that TGF␤1 and its receptor (type II) are expressed in human adrenocortical cells (8) .
The present study was designed to investigate whether TGF␤1 is involved in DHT action on human adrenocortical cells. In particular, we studied the effect of DHT on TGF␤1 expression in NCI-H295 cells and the effect of TGF␤1 on human adrenocortical cell growth by assessing the response of these cells to exogenous TGF␤1 in terms of [ 3 H]thymidine ([ 3 H]thy) incorporation. Evidence is provided to demonstrate that DHT-induced growth inhibition could be mediated at least in part by TGF␤1.
Materials and Methods

NCI-H295 cell line culture
The human NCI-H295 adrenocortical cancer cell line was obtained from the American Type Culture Collection (Manassas, VA). Cells were maintained in RPMI 1640 medium without phenol red and with lglutamine supplemented with 2% FCS and containing sodium selenite (1 ng/mL), insulin (5 g/mL; Novo Nordisk, Princeton, NJ), transferrin (5 g/mL), dexamethasone (10 Ϫ8 mol/L), 17␤-estradiol (10 Ϫ8 mol/L), 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 100 g/mL amphotericin at 37 C in a humidified atmosphere of 5% CO 2 and 95% air. To eliminate the influence of steroid hormones in the medium, cells were switched to RPMI 1640 medium supplemented with 2% dextran (0.1%)-coated charcoal (1%)-treated FCS (DCT-FCS), sodium selenite (1 ng/ mL), insulin (5 g/mL), transferrin (5 g/mL), and antibiotics before incubation with hormones.
After overnight growth, subconfluent NCI-H295 cells were incubated in the absence (control untreated cells) or presence of DHT at the indicated concentrations in medium without steroids and supplemented with 2% DCT-FCS. DHT was added to the medium in alcohol, at a final ethanol concentration less than 0.1% in both the control and hormonetreated cultures. TGF␤1 protein production was measured in conditioned media from culture flasks, and TGF␤1 messenger ribonucleic acid (mRNA) expression was evaluated after total RNA extraction from cells harvested by trypsinization. Cell culture and chemical reagents were purchased from Mascia Brunelli (Milan, Italy) and Sigma (Milan, Italy), respectively, unless otherwise indicated.
Isolation of RNA
Total RNA was extracted from subconfluent NCI-H295 cells using the Ultraspec-II RNA Isolation System (Biotecx Laboratories, Inc., Houston, TX). To prevent DNA contamination, RNA was treated with ribonuclease-free deoxyribonuclease. The amount of total RNA was determined by optical density at 260 nm.
RT-PCR
Using a first strand complementary DNA (cDNA) synthesis kit (Roche, Mannheim, Germany), 1 g total RNA was reverse transcribed according to the manufacturer's protocol. RT mix in PCR tubes was covered with 50 L light white mineral oil (Sigma-Aldrich Corp., Milan, Italy); the RT was carried out in the Minicycler (MJ Research, Inc., Watertown, MA) using a program with the following parameters: 10 min at 24 C, 60 min at 42 C, 5 min at 95 C, and 5 min at 4 C. After the reaction was completed, samples were stored at Ϫ20 C until the first PCR.
The complementary DNA (1 L RT reaction) was then amplified by PCR in 30 cycles with 1 U Taq polymerase (Roche) in the conditions recommended by suppliers in a 25-L reaction mixture. After initial denaturation at 95 C for 5 min, each cycle consisted of primer annealing at 63 C for 1 min, extension at 72 C for 1.5 min, denaturation at 95 C for 1 min, and final extension at 72 C for 10 min. Oligonucleotide primer sequences used for the amplification were: 1447-1470, 5Ј-CGGAGTT-GTGCGGCAGTGGTTGA-3Ј (forward); and 1871-1894, 5Ј-GCGC-CCGGGTTATGCTGGTTGTA-3Ј (reverse), located, respectively, in exons 3 and 7 of the human TGF␤1 gene. These are expected to amplify a TGF␤1 cDNA fragment 450 bp in size. PCR products were analyzed on a 2% agarose gel and visualized by ethidium bromide (ETB) staining.
To assure that no contamination occurred during the course of the RT-PCR procedure, two kinds of negative control were prepared. The first negative control was made by omitting the total RNA in the RT. The second was prepared by replacing the cDNA mix with water in the PCR reaction. The PCR was considered useful only if no band was observed in the negative control lanes on a 2% agarose gel.
For determination of TGF␤1 mRNA, competitive quantitative RT-PCR was performed (9) .
Construction of the target cDNA and competitive fragment for TGF␤1
A 450-bp fragment of native TGF␤1 cDNA (i.e. target) was obtained by PCR amplification of reverse transcribed total RNA from a human breast cancer cell line, MCF7, which is known to constitutively express TGF␤1 (3). The PCR product was visualized by agarose gel electrophoresis and stained with ETB. The cDNA was extracted and purified from the gel with the Prep-A-Gene DNA purification kit (Bio-Rad Laboratories, Inc., Milan, Italy). By determination of the optical density we estimated the concentration (micrograms per L) of the target cDNA; the absolute number of target cDNA molecules was then calculated (10) using the following formula:
The mol wt of target cDNA was 270 g/mol, and Avogadro's number was 6.023 ϫ 10 23 molecules/mol. The solution was aliquoted in serial dilutions and stored at Ϫ20 C.
To generate an internal standard, a previously described, low stringency PCR method was used (11) . Briefly, RT-PCR was carried out at a lower annealing temperature (55 C) to decrease the stringency of priming. Lower stringency, indeed, allows more mismatches in primer sequences, yielding multiple products. As a competitor for the native TGF␤1 message, a 200-bp fragment was selected and purified from agarose gel as previously described. Subsequently, the fragment was reamplified at the 60 C annealing temperature to determine its feasibility as a competitor for the native TGF␤1 cDNA. The expected 200-bp fragment was again obtained and then used to compete with the native TGF␤1 cDNA for the primers. The concentration of competitor fragment (CF) was estimated as described above.
Standard curve and competitive quantitative PCR
The standard curve for TGF␤1 was constructed as previously described by Krussel et al. (12) . A constant amount of CF (5 ϫ 10 4 molecules) was coamplified with declining amounts of target cDNA, obtained by serial dilutions. The amounts of target cDNA that were added to each PCR are shown in Fig. 1 . PCR for TGF␤1 was performed as described above; the products were resolved on 2% agarose gel stained with ETB and analyzed on the Fluor-S system (Bio-Rad Laboratories, Inc.). cDNA size calculation and UV densitometry were carried out using MultiAnalyst software (Bio-Rad Laboratories, Inc.). The logarithmically transformed ratio of the ETB densities of target cDNA to CF was calculated and plotted against the log amount of initially added target cDNA in each PCR to obtain the standard curves shown in Fig. 1 . Simple regression analysis showed a significant correlation (r 2 ϭ 0.9938; P Ͻ 0.001) between these two parameters. The values obtained from the regression line of the standard curve (y ϭ b ϩ ax) allowed us to measure the amount of cDNA TGF␤1 transcripts in an unknown sample when coamplified with 5 ϫ 10 4 molecules of CF. The ratio of the densities of the CF band (200 bp) and the target cDNA band obtained from each sample (450 bp) was logarithmically transformed and compared to the value obtained from the standard curve [x ϭ (y Ϫ b)/a]. The reproducibility of this method (quantitative PCR) was tested by repeating the assay using independent control RNAs. The interassay coefficient of variation ranged from 2-3.7%. Quantitative PCR was performed on duplicate RT samples from RNA extracted from control and DHT-treated (10
Determination of TGF␤1 protein secretion by NCI-H295 cells
TGF␤1 immunoassay was performed using the TGF␤1 E max Immunoassay System (Promega Corp., Madison, WI), which measures the level of biologically active TGF␤1. Active TGF␤1 was directly measured in cell culture media, and latent TGF␤1 was indirectly determined after acid activation (0.1 n HCl) to convert any latent TGF␤1 to the active form. All samples from conditioned media were assayed before and after acid activation to determine the amount of biologically active and total (latent plus biologically active) TGF␤1, respectively. All samples from each experiment were processed in duplicate in the same assay. The lowest detection limit was 25 pg/mL TGF␤1. Cross-reaction with TGF␤2 and TGF␤3 at 10 ng/mL was 5% or less. The interassay coefficient of variation for the TGF␤1 method ranged from 6 -11%. The intraassay coefficient of variation ranged from 3.2-5.1%. Results (nanograms per mL) were obtained by determining the mean value in culture medium collected from untreated control and DHT (10 Ϫ11 -10 Ϫ8 mol/L)-treated cells in at least seven independent experiments.
DNA synthesis
The rate of [ 3 H]thy incorporation was determined as previously described (13) . NCI-H295 cells were plated in 24-multiwell plates (10 5 cells/well) and incubated for 24 h in a medium supplemented with DCT-FCS in the presence of [ 3 H]thy (1.5 Ci/mL; 87 Ci/mmol) with or without TGF␤1 at concentrations from 10
Ϫ6 mol/L. In assays blocking the effects of DHT-induced TGF␤1, NCI-H295 cells were treated with or without DHT (10 Ϫ10 and 10 Ϫ9 mol/L) and with or without 0.2 g/mL TGF␤1 neutralizing antibody (anti-TGF␤1 pAB, Promega Corp.). A similar concentration of normal rabbit IgG was used as a negative control.
After incubation, the cells were washed three times with ice-cold PBS and twice with 10% ice-cold trichloroacetic acid (TCA). TCA-precipitable material was solubilized in 500 L 0.2 mol/L sodium hydroxide and 0.1% SDS. Cell-associated radioactivity was then counted in a scintillation spectrometer. Results (counts per min/well) were obtained by determining the mean value of at least seven experiments in quadruplicate. The viability of NCI-H295 cells in control and treated cultures was evaluated by trypan blue staining, and the number of viable cells was always 85-95%.
Statistical analysis
Unless otherwise indicated, the values are expressed as the mean Ϯ se. A preliminary analysis was carried out to determine whether the datasets conformed to a normal distribution, and a computation of homogeneity of variance was performed using Bartlett's test. Because of the inherent variability in the datasets and the skewed nature of the distribution of the results, all values were logarithmically transformed before statistical analysis. The results were compared within each group and between groups using ANOVA. If the F values were significant (P Ͻ 0.05), Student's paired or unpaired t test was used to evaluate individual differences between means.
Results
DHT-induced TGF␤1 gene expression in NCI-H295 cells
After 24 h of treatment, DHT significantly (P Ͻ 0.001) induced TGF␤1 mRNA expression in the NCI-H295 adrenocortical cancer cell line at concentrations ranging from 10 Ϫ12 -10 Ϫ8 mol/L, with a 12-to 14-fold increase compared with the control value and in a dose-dependent fashion (Fig.  2) . The time course (Fig. 3 ) of TGF␤1 gene induction by DHT (10 Ϫ9 mol/L) showed that TGF␤1 mRNA levels increased time-dependently. DHT caused a significant increase in TGF␤1 mRNA expression after 4 and 12 h (P Ͻ 0.05) and after 24 h (P Ͻ 0.01).
Effect of DHT on TGF␤1 protein
After 24-h incubation with DHT (10 Ϫ11 -10 Ϫ8 mol/L; Fig.  4 ), the levels of biologically active TGF␤1 in the culture medium of NCI-H295 cells were significantly (P Ͻ 0.05) higher than those detected in the culture medium of untreated control NCI-H295 cells (7.5 Ϯ 0.6 ng/mL), showing a 2-fold induction (15 Ϯ 0.9 ng/mL) at 10 Ϫ10 -10 Ϫ8 mol/L. On the other hand, the latent form did not significantly change during DHT treatment.
Effect of TGF␤1 on [ 3 H]thy incorporation
Data from seven individual experiments are expressed as the percentage over the value in untreated control cells. As 
Effects of DHT and TGF␤1 neutralizing antibody on [ 3 H]thy incorporation
To investigate whether TGF␤1 is involved in the growth inhibition induced by DHT, the action of TGF␤1 was blocked using a commercially available TGF␤1-neutralizing antibody. This antibody is identical to the one used for enzymelinked immunosorbent assay. Figure 6 shows the results of seven independent experiments. As expected, DHT treatment significantly (P Ͼ 0.05) reduced [ 3 H]thy incorporation in NCI-H295 cells at both 10 Ϫ10 and 10 Ϫ9 mol/L by nearly 50%. The administration of DHT together with a TGF␤1-neutralizing antibody was associated with a significant (P Ͻ 0.001) increase (2.2-fold) in [ 3 H]thy incorporation. When the antibody was administered alone, [ 3 H]thy incorporation increased significantly (P Ͻ 0.01) by nearly 50% compared with untreated control cells. Normal rabbit IgG did not influence the rate of DNA synthesis in NCI-H295 cells (data not shown).
Discussion
We here documented that DHT induces a significant increase in TGF␤1 expression and production in NCI-H295 cells. It is well known that androgens influence adrenocortical function, morphology, and steroidogenesis (14, 15) . In previous studies it has been reported that androgen treatment induces atrophy in male rat adrenal cortex (16, 17) . We recently demonstrated that DHT inhibits cell proliferation in the human adrenal gland by a receptor-mediated mechanism (7). Furthermore, members of the steroid hormone superfamily are known to regulate the production of TGF␤ in vitro in a tissue-specific manner (18 -20) .
AR, which we found to be expressed in human adrenocortical tissues and cells (7), is a member of the steroid/ thyroid receptor superfamily and, as such, is a transcription factor modulating gene expression in an androgen-dependent manner. Our results indicate that in a human adrenocortical cell line, DHT is capable of up-regulating both TGF␤1 mRNA and protein, suggesting a possible regulatory mechanism at the transcriptional level. However, we cannot exclude that TGF␤1 expression could be regulated posttranscriptionally, as suggested by Kim et al. (21) , who demonstrated that the 5Ј-untranslated region of TGF␤1 mRNA inhibits translation. Moreover, DHT could enhance TGF␤1 transcription through an indirect pathway, as no androgenresponsive elements are present in the human TGF␤1 gene promoter.
The demonstration that the majority of TGF␤1 detected in conditioned media from DHT-treated NCI-H295 cells was biologically active, provides evidence that NCI-H295 cells are capable of activating TGF␤1 protein in vitro. These results are in line with previous in vitro data showing that a significant fraction of TGF␤1 secreted by cultured human cells is in the biologically active form (6) .
We previously documented the presence of type II TGF␤ receptor in the human adrenocortical cancer cell line, NCI-H295, and that its expression can be enhanced by DHT treatment (8) . This finding is consistent with the hypothesis of a TGF␤1-mediated effect of DHT on adrenocortical gland proliferation and may provide the basis for an autocrine/paracrine role for TGF␤1 in this model. In the present study we found that TGF␤1 significantly reduced [ 3 H]thy incorporation in NCI-H295 cells. As [
3 H]thy incorporation in the cells may be considered an indirect parameter of DNA synthesis, these results suggest that TGF␤1 may exert an inhibitory action on adrenocortical cell DNA synthesis. The addition of TGF␤1-neutralizing antibody to DHT-treated and untreated NCI-H295 cells produced a higher [ 3 H]thy incorporation rate, indicating that the antibody counteracts the effect of both DHT-induced and constitutive TGF␤1. This finding is in line with our data demonstrating that NCI-H295 cells constitutively produce TGF␤1, which becomes a likely candidate for autocrine cell growth control. The demonstration that DHT enhances this putative autocrine feedback circuit could explain at least in part the inhibitory action of androgen on human adrenocortical cell proliferation. Furthermore, the normal human adrenal gland is known to express TGF␤1, which inhibits human fetal adrenal growth (5) . This provides the basis for the hypothesis that TGF␤1 may exert autocrine/ paracrine control on normal adrenocortical cell proliferation. Our experimental model cannot determine to what extent androgen could influence this system in the normal gland.
The demonstration of an antiproliferative action of TGF␤1 on human adrenocortical cells is in accordance with previous evidence that this factor inhibits fetal and definitive adrenocortical cell proliferation (22, 23) , possibly hampering the progression through the G 1 phase of the cell cycle. Moreover, as recently described in the rat testis (24) and human endometrial epithelial cells (25) , TGF␤1 could reduce cell growth, triggering an apoptotic signal in adrenocortical cells. Szelei et al. (26) found that natural and synthetic androgens prevent MCF7 cells, stably transfected with a full human AR vector, from proliferating. The same effect was observed when these cells were cultured with serum-supplemented medium, suggesting that sex steroid target cells may be sensitive to a serum-borne component that conveys an inhibitory signal when cells enter the cell cycle. TGF␤1 is highly represented in serum; therefore, we can argue that it could be an important component of the inhibitory complex influencing ARpositive cell proliferation. Besides, TGF␤1 has been shown to inhibit epithelial cell growth in the absence of serum (27) in concordance with our data. This could suggest that TGF␤1 does not require another serum-borne factor to be active. At the same time, up-regulation of collagen and matrix protein synthesis by the secreted TGF␤1 could influence the proliferative rate of adrenocortical cells in vivo.
Recently, Boccuzzi et al. (28) showed by immunohistochemistry that adrenal carcinoma has very faint, if any, TGF␤1 expression, whereas normal adrenal gland exhibits variable degrees of intensity of TGF␤1 staining in the different layers. This would be in line with the idea that TGF␤1 modulates adrenocortical cell proliferation and that the lack of TGF␤1 expression might be correlated with more undifferentiated and highly proliferative pattern of neoplasia, whereas well differentiated and normally cycling cells express this cytokine at apparently detectable levels. By contrast, we found that the NCI-H295 cell line, derived from a human adrenocortical carcinoma, spontaneously produces quite high amounts of TGF␤1, and that immunoneutralization of TGF␤1 by a specific antibody is associated with greater [
3 H]thy incorporation in these cells. At present we are not able to exclude that other factors could influence the proliferation of adrenocortical cells in this model.
In conclusion, this study indicates that DHT treatment is associated with an increase in TGF␤1 expression and production and that TGF␤1 reduces the proliferation of the adrenocortical cancer cell line in vitro. We speculate that TGF␤1 could account at least in part for the inhibitory effect of DHT on human adrenocortical cell growth that we have previously demonstrated (7) .
